Scinai Immunotherapeutics
SCNI
17 hedge funds and large institutions have $544K invested in Scinai Immunotherapeutics in 2022 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 2 closing their positions.
300% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 2
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
42% more funds holding
Funds holding: 12 → 17 (+5)
0.07% less ownership
Funds ownership: 1.82% → 1.75% (-0.07%)
35% less capital inflows, than outflows
Capital inflows: $202K | Capital outflows: $313K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$81.3K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$61K |
| 3 |
Millennium Management
New York
|
+$29K |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$7.26K |
| 5 |
Morgan Stanley
New York
|
+$5.81K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$200K |
| 2 |
ExodusPoint Capital Management
New York
|
-$74K |
| 3 |
Two Sigma Securities
New York
|
-$37.7K |
| 4 |
JP Morgan Chase
New York
|
-$1K |
SCNI Hedge Fund Activity: Q1 2022 in Review
17 of the 6,364 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q1 2022, worth a combined $544K — down 31% from $789K a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new SCNI positions and 2 closed out — a net gain of 6 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $81.3K. The largest seller was State Street, exiting entirely with an estimated $200K sold.
- 17 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q1 2022, up from 12 in Q4 2021.
- Funds reported $544K of Scinai Immunotherapeutics stock for Q1 2022, down 31% quarter-over-quarter.
- 8 funds opened new Scinai Immunotherapeutics positions in Q1 2022 and 2 closed out, a net change of +6 holders.
- The largest Scinai Immunotherapeutics buyer in Q1 2022 was Susquehanna International Group, an estimated $81.3K added.
- The largest Scinai Immunotherapeutics seller in Q1 2022 was State Street, an estimated $200K sold.
Based on aggregated 13F filings for Q1 2022.